Suven Life Sciences slumped 8.56% to Rs 98.30 after the company reported a consolidated net loss of Rs 21.69 crore in Q4 FY21 compared with net loss of Rs 25.74 crore in Q4 FY20.
Total income during the quarter tumbled 75.3% year-on-year to Rs 2.88 crore. R&D and operational expense declined 31.4% to Rs 23.13 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, the company reported a net loss of Rs 72.45 crore in the year ended 31 March 2021 compared with net loss of Rs 94.51 crore the year ended 31 March 2020. Total income fell 25.4% to Rs 21.23 crore in FY21 over FY20.
Suven Life Sciences, a biopharmaceutical company, engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app